Kuang YY, Xiong MQ, Cai JX. Clinical efficacy of gamma-oryzanol combined with Femoston for perimenopausal syndrome. World J Clin Cases 2024; 12(22): 4992-4998 [DOI: 10.12998/wjcc.v12.i22.4992]
Corresponding Author of This Article
Yang-Yang Kuang, MM, Doctor, Women's Health Management Center, Jiujiang Maternal and Child Health Hospital, No. 61 Gantang South Road, Xunyang District, Jiujiang 332000, Jiangxi Province, China. 13576207600@163.com
Research Domain of This Article
Obstetrics & Gynecology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 6, 2024; 12(22): 4992-4998 Published online Aug 6, 2024. doi: 10.12998/wjcc.v12.i22.4992
Clinical efficacy of gamma-oryzanol combined with Femoston for perimenopausal syndrome
Yang-Yang Kuang, Min-Qi Xiong, Jin-Xia Cai
Yang-Yang Kuang, Min-Qi Xiong, Jin-Xia Cai, Women's Health Management Center, Jiujiang Maternal and Child Health Hospital, Jiujiang 332000, Jiangxi Province, China
Author contributions: Kuang YY participated in the study design and wrote the manuscript; Kuang YY conducted the design of the study and reviewed/edited the drafts, and is guarantor; Kuang YY, Xiong MQ, and Cai JX collected and analyzed the data; Kuang YY revised the manuscript. All authors contributed to the article and approved the submitted article.
Institutional review board statement: This study was approved by the Ethic Committee of Jiujiang Maternal and Child Health Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All authors have no conflicts of interest to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yang-Yang Kuang, MM, Doctor, Women's Health Management Center, Jiujiang Maternal and Child Health Hospital, No. 61 Gantang South Road, Xunyang District, Jiujiang 332000, Jiangxi Province, China. 13576207600@163.com
Received: April 30, 2024 Revised: May 29, 2024 Accepted: June 14, 2024 Published online: August 6, 2024 Processing time: 62 Days and 21.8 Hours
Abstract
BACKGROUND
Perimenopausal syndrome (PMS) is a chronic disease associated with estrogen deficiency. Because of the unsatisfactory outcomes of current conventional treatments for this condition, its treatment must be continuously explored and optimized.
AIM
To assess the clinical effectiveness of γ-oryzanol in combination with Femoston for PMS.
METHODS
A total of 119 patients with PMS were selected from June 2023 to December 2023, which included 59 and 60 patients in the control and observation group, respectively. The control and observation groups were treated with Femoston and γ-oryzanol + Femoston, respectively. Comparative analyses were performed in terms of clinical effectiveness, safety (dizziness and headache, nausea and vomiting, and breast tenderness), sex hormones [estradiol (E2), luteinizing hormone (LH), and follicle-stimulating hormone (FSH)], lumbar spine (L1–4) and bilateral femoral bone mineral density (BMD), and sleep quality (sleeping time and frequency of awakenings from sleep).
RESULTS
Compared with the control group, the observation group had statistically higher total effective rates of treatment; lower overall incidence of adverse events; higher post-treatment E2 levels and L1–4 and bilateral femoral BMD; and lower LH and FSH levels, sleeping time, and frequency of awakenings from sleep after treatment.
CONCLUSION
Therefore, for the treatment of PMS, γ-oryzanol combined with Femoston is significantly better than Femoston alone in terms of clinical effectiveness, exhibiting more pronounced clinical advantages in improving safety, sex hormone levels, BMD, and sleep quality.
Core Tip: Perimenopausal syndrome (PMS) is a chronic condition associated with estrogen deficiency. Hormone replacement therapy is the conventional treatment for PMS; however, because of possible adverse events such as stroke, breast cancer, endometrial cancer, glucose intolerance, and thromboembolic disease, its treatment alternatives must be continuously explored and optimized. Compared with Femoston monotherapy, proposed combination therapy of γ-oryzanol and Femoston has certain clinical advantages, including significantly better clinical efficacy, for treating patients with PMS. This treatment can prevent adverse reactions, actively regulate sex hormone levels, increase patient bone mineral density, and actively help improve sleep quality.
